


# LISTING OF CLAIMS

Claims 1-8 (CANCELED)

9- (NEW) A composition comprising a combination of compound (A) of formula (I), optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof, and aspirin, or a pharmaceutically acceptable salt thereof:



10- (NEW) The composition of claim 9, wherein compound (A) has the (R) configuration.

11- (NEW) The composition of claim 9, wherein compound (A) is in the form of a sodium salt.

12- (NEW) A pharmaceutical composition comprising as active ingredients a combination of compound (A), optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof, and aspirin, or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable, inert excipients or carriers.

13- (NEW) The pharmaceutical composition of claim 12, wherein compound (A) has the (R) configuration.

14- (NEW) The pharmaceutical composition of claim 12, wherein compound (A) is in the form of a sodium salt.

15- (NEW) The pharmaceutical composition of claim 12, wherein the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for compound (A) and from 10 to 1000 mg for aspirin.

16- (NEW) A method for treating a living animal body, including a human, afflicted with an atherothrombotic illness involving activation of TP receptors and/or formation of metabolites, comprising the step of administering to the living animal body, including a human, an amount of a composition of claim 9 which is effective for alleviation of the  
5 atherothrombotic illness.